A new vaccine is more effective than previous vaccines in preventing coronavirus (COVID-19) in Australia, according to a study by the US Centers for Disease Control and Prevention (CDC).
The new vaccine, called L5S, is being tested in people aged 15 to 74 in the US.
The CDC’s Dr. Michael Reiter said in a statement: “Our research shows that L5s vaccine, as currently tested, is substantially more effective at preventing COVID-18 than previous COVID vaccines.”
The L5 vaccines, which were previously tested in a small population in the UK, were also effective against other major coronaviruses, such as influenza and other influenza-like viruses.””
While we are now testing the L5 vaccine in a larger population, we believe L5 is far more effective in preventing COVI-18,” Dr Reiter added.”
Our analysis suggests that L6s vaccine is also significantly less effective at stopping COVI.
“Both vaccines, L5 and L6, are being tested to help protect people from COVI, but we cannot predict how well they will work in preventing and controlling COVID,” Dr Rein said.
“As with any vaccine, the benefits and risks of L5, L6 and L7 vaccines will depend on how well the vaccine is working in a given population.”
However, based on the data we have at this time, it is clear that L7 is a far more appropriate vaccine for COVI than L5.
“These findings are the result of a long-term, rigorous study of the safety and efficacy of the L7 vaccine in adults aged 15-74, and the effectiveness of the current L5 versus the previous L5,” Dr Richard Lee, a vaccine expert and research fellow at the Vaccine Development Institute, said.
“This study shows that, based solely on this small number of participants, L7 has significantly higher efficacy than previous L7 vaccinations in preventing the coronaviral disease coronavieptiomyelitis.”
The L7 was first approved by the FDA in November 2016, and has been approved by more than 100 other countries and territories around the world.
It was first tested in humans in the United Kingdom in 2016 and is being used in Europe, Japan, Australia, Canada and the United States.
The FDA also approved the vaccine in Australia in September.
The L6 vaccine, L3, was approved by US health officials in July 2018 and is currently being tested by the United Nations and in countries in Africa, Asia and Latin America.
The latest L5 test results are the second time the CDC has seen an increase in the vaccine effectiveness of an older vaccine, which was first trialled in the 1980s.
The agency said in January 2018 that L4 had the highest efficacy against COVID, followed by L5 at 74.
In September 2018, the US FDA approved L6 for the US market.
Dr Reiter’s study, which will be published in the Journal of the American Medical Association, is the first to use data from a large-scale, double-blind trial of the vaccines.
Dr Reiters study involved a randomised, placebo-controlled trial in adults with COVID and a cohort of people aged 40 to 64, who were randomly assigned to receive either L5 or L6 or to receive no vaccine.
There were 5,738 participants in the study, of whom 2,746 had been vaccinated against COVI and the other 2,096 had not been vaccinated.
Study participants had no previous history of COVID.
For the COVID trial, people aged between 20 and 74 were recruited by mail and enrolled in a placebo-cohort trial, which meant they received a vaccine, but they did not get an actual shot.
Participants were randomly divided into three groups.
Each group received L5 (preferred), L6 (unlikely to benefit from the vaccine) or no vaccine (no benefit).
They then underwent a blood draw and had their blood analysed to measure levels of COVI virus antibodies.
They were also asked about their vaccination history, including their vaccine history and whether they had previously received any vaccinations.
Results showed the L6 group had the lowest level of COV-1 antibody and the highest level of antibody to COVID virus compared to the L3 group.
While the L2 group had significantly higher levels of antibodies to COVI compared to their L5 group, they had no significant differences in the levels of other viruses, such of coronavireptiomys, coronavirocoviruses or tetanus toxoids.
Researchers say the results suggest that L3 is more protective against COV than L6.
“This is consistent with previous studies, which have shown